Skip to main content
Premium Trial:

Request an Annual Quote

NantOmics Buys Remaining Shares of OncoPlex Dx

NEW YORK (GenomeWeb) – NantOmics announced today it has acquired the remaining shares of OncoPlex Diagnostics that it didn't already own. 

The terms of the deal were not disclosed. 

NantOmics is a molecular diagnostics firm and part of the NantWorks network of firms founded by Patrick Soon-Shion. His companies have funded OncoPlex since 2008, NantOmics said. 

OncoPlex operates a CAP-accredited and CLIA-certified laboratory in Rockville, Maryland, where the firm is headquartered, and provides mass spectrometry-based tumor profiling services aimed at improving treatment decisions. 

"With this integration, we have added state-of-the-art discovery tools and a complementary array of molecular diagnostic services and tests," Soon-Shiong said in a statement. "More importantly, we have enhanced our ability to deliver patient-specific pan-omic information and, ultimately, improve disease diagnosis and therapy." 

"By combining DNA sequencing, RNA sequencing, and protein expression utilizing mass spectrometry, NantOmics can now offer expanded testing capabilities that provide a broader and more comprehensive picture of a patient's unique tumor biology," OncoPlex CSO Todd Hembrough added.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.